Multi‐state Markov models for disease progression in the presence of informative examination times: An application to hepatitis C

In many chronic diseases it is important to understand the rate at which patients progress from infection through a series of defined disease states to a clinical outcome, e.g. cirrhosis in hepatitis C virus (HCV)-infected individuals or AIDS in HIV-infected individuals. Typically data are obtained from longitudinal studies, which often are observational in nature, and where disease state is observed only at selected examinations throughout follow-up. Transition times between disease states are therefore interval censored. Multi-state Markov models are commonly used to analyze such data, but rely on the assumption that the examination times are non-informative, and hence the examination process is ignorable in a likelihood-based analysis. In this paper we develop a Markov model that relaxes this assumption through the premise that the examination process is ignorable only after conditioning on a more regularly observed auxiliary variable. This situation arises in a study of HCV disease progression, where liver biopsies (the examinations) are sparse, irregular, and potentially informative with respect to the transition times. We use additional information on liver function tests (LFTs), commonly collected throughout follow-up, to inform current disease state and to assume an ignorable examination process. The model developed has a similar structure to a hidden Markov model and accommodates both the series of LFT measurements and the partially latent series of disease states. We show through simulation how this model compares with the commonly used ignorable Markov model, and a Markov model that assumes the examination process is non-ignorable.

[1]  Stuart R. Lipsitz,et al.  Analysis of longitudinal data with non‐ignorable non‐monotone missing values , 2002 .

[2]  J F Lawless,et al.  Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease. , 1994, Statistics in medicine.

[3]  M. Kenward Selection models for repeated measurements with non-random dropout: an illustration of sensitivity. , 1998, Statistics in medicine.

[4]  Simon G. Thompson,et al.  Multistate Markov models for disease progression with classification error , 2003 .

[5]  M. Kenward,et al.  Informative Drop‐Out in Longitudinal Data Analysis , 1994 .

[6]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[7]  Roderick J. A. Little,et al.  Modeling the Drop-Out Mechanism in Repeated-Measures Studies , 1995 .

[8]  D Commenges,et al.  Incidence and mortality of Alzheimer's disease or dementia using an illness‐death model , 2004, Statistics in medicine.

[9]  R H Jones,et al.  Multi-state models and diabetic retinopathy. , 1995, Statistics in medicine.

[10]  J. Kalbfleisch,et al.  The Analysis of Panel Data under a Markov Assumption , 1985 .

[11]  A. Valleron,et al.  Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model , 2002, Journal of viral hepatitis.

[12]  G A Satten,et al.  Discrete‐Time Nonparametric Estimation for Semi‐Markov Models of Chain‐of‐Events Data Subject to Interval Censoring and Truncation , 1999, Biometrics.

[13]  J Grüger,et al.  The validity of inferences based on incomplete observations in disease state models. , 1991, Biometrics.

[14]  Peter J. Diggle,et al.  Analysis of longitudinal data with drop‐out: objectives, assumptions and a proposal , 2007 .

[15]  Juan Eloy Ruiz-Castro,et al.  Non‐homogeneous Markov models in the analysis of survival after breast cancer , 2001 .

[16]  Arakawa,et al.  Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C – a study of 527 patients at one establishment , 2000, Journal of viral hepatitis.

[17]  R Kay,et al.  A Markov model for analysing cancer markers and disease states in survival studies. , 1986, Biometrics.

[18]  Stephen W Lagakos,et al.  Statistical methods for panel data from a semi-Markov process, with application to HPV. , 2007, Biostatistics.

[19]  Joseph W Hogan,et al.  Handling drop‐out in longitudinal studies , 2004, Statistics in medicine.

[20]  M. Kenward,et al.  Informative dropout in longitudinal data analysis (with discussion) , 1994 .

[21]  Paul S. Albert,et al.  A Random Effects Transition Model For Longitudinal Binary Data With Informative Missingness , 2003 .

[22]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[23]  Marco Bonetti,et al.  A multistate Markov chain model for longitudinal, categorical quality‐of‐life data subject to non‐ignorable missingness , 2005, Statistics in medicine.

[24]  Christopher H Jackson,et al.  Hidden Markov models for the onset and progression of bronchiolitis obliterans syndrome in lung transplant recipients , 2002, Statistics in medicine.

[25]  D. Rubin INFERENCE AND MISSING DATA , 1975 .

[26]  A. Mohsen,et al.  The epidemiology of hepatitis C in a UK health regional population of 5.12 million , 2001, Gut.

[27]  S. Richardson,et al.  Stochastic Algorithms for Markov Models Estimation with Intermittent Missing Data , 1999, Biometrics.

[28]  G Molenberghs,et al.  Sensitivity Analysis for Nonrandom Dropout: A Local Influence Approach , 2001, Biometrics.

[29]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.